Monitor the outcome of the Type D FDA meeting in August 2026 for clarity on the registrational path. The year-end 2026 Part A tumor response data will be the next key catalyst. Until then, the stock is likely to trade on trial execution milestones and broader biotech sentiment.
Price Chart
Executive Summary
Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, reporting that half of planned clinical sites will be activated by end of July with over 20 patients pre-identified. The company will hold a Type D meeting with the FDA in early August 2026 to discuss adding a registrational Part B to the study, which could support accelerated and full approval. Initial tumor response data from Part A is expected by year-end 2026, with Part B enrollment potentially starting Q1 2027.
Key Facts
- Half of planned clinical sites for REO 033 will be activated by end of July 2026; over 20 patients pre-identified across centers.
- Type D meeting with FDA scheduled for first half of August 2026 to discuss registrational expansion via Part B of REO 033.
- Part B designed as a randomized study with blinded independent central review to support potential accelerated and full approval.
- Initial tumor response update from Part A expected by year-end 2026; Part B enrollment targeted for Q1 2027 subject to FDA feedback.
- Pelareorep has Fast Track designation from FDA for colorectal cancer indication.
Financial Impact
No financial figures reported; filing is a clinical and regulatory update with no revenue or cost disclosures.
Risk Factors
- FDA may not agree to the proposed registrational design, delaying or altering the pathway.
- Clinical trial enrollment or data may disappoint, particularly given the challenging RAS-mutant MSS CRC indication.
- Company is pre-revenue and may require additional financing to complete the expanded study.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000043 |
| Document: oncolyticsreo033update.htm | 0001129928-26-000043 |
| Document: 0001129928-26-000043-index-headers.html | 0001129928-26-000043 |
| Document: 0001129928-26-000043-index.html | 0001129928-26-000043 |
| Document: 0001129928-26-000043.txt | 0001129928-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access